Busan, South Korea
Busan, South Korea

Kosin university is a private Christian university in Busan, South Korea. The name "Kosin" is derived from the name of a denominaton of presbyterian churches in Korea that had organized actions against the empire of Japan. This university was established in 1946 at the end of Japanese rule in Korea. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

News Article | May 17, 2017
Site: www.prnewswire.co.uk

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 164-page report you will receive 84 tables and 93 figures - all unavailable elsewhere. The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. • Revenue forecasts of global erythropoietin market, segmented by product type: - Epoetin Alfa - Epoetin Beta - Darbepoetin Alfa - Biosimilars - Others This section also discusses the leading drugs as well as SWOT analysis of each submarket. • Revenue forecasts of global erythropoietin market, segmented by application: - Anemia (Cancer and HIV Treatment) - Kidney Disorders (ESRD and Dialysis) - Others Forecast for each regional market is further segmented by product type, application and country: - US - Canada - UK - Germany - France - Spain - Italy - Rest of Europe - China - Japan - India - Rest of Asia-Pacific - Brazil - Mexico - Rest of Latin America - Saudi Arabia - South Africa - Rest of Middle East and Africa • Assessment of selected leading companies that hold major market shares in the erythropoietin market: - Amgen - Johnson & Johnson - Roche - Biocon - 3SBio - Pfizer - Kyowa Hakko Kirin Co Ltd - LG Life Sciences Limited - Intas Pharmaceuticals Ltd - Novartis AG Visiongain's study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 3SBio Inc. Accord Healthcare Limited Actavis Akebia Therapeutics Amgen Astellas Pharma Inc AstraZeneca Bio Sidus SA Biocon Ltd Casa Marzam Casa Saba Chugai Pharmaceutical Claes-Göran Östenson Corvidia Therapeutics DaVita Inc Dr. Reddy's Laboratories FibroGen First Shanghai Investments Limited Fresenius Medical Care North America (FMCNA) Galenica Germans Trias i Pujol Hospital GlaxoSmithKline H. Lundbeck A/S Hoffmann-La Roche Hospira Janssen Biotech Japan Chemical Research Pharmaceuticals Co., Ltd. Johnson & Johnson Kissei pharmaceuticals Kosin University Gospel Hospital Kyowa Hakko Kirin Co Ltd LG Life Sciences Limited NADRO NovaQuest Co-Investment Fund I, L.P. Novartis Institutes for BioMedical Research (NIBR) Novartis Pharmaceuticals NOXXON Pharma AG Pfizer Proveedora de Medicamentos RPG Life Sciences Sandoz Sirton Pharma Stada Stem Cell Therapeutics Corp. Teva Pharmaceutical Industries Ltd. UBI Pharma Inc. Vifor Pharma List of Organizations Mentioned in the Report Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) Centers of Disease Control and Preventions China's Ministry of Health (MOH) Committee for Medicinal Products for Human Use (CHMP) Department of Health & Family Welfare of Karnataka Deutsches Ärzteblatt EMA European Commission (EC) FDA Indian Council of Medical Research (ICMR) International Agency for Research on Cancer (IARC) Ministry of Health, Malaysia National Cancer Institute National Center for Biotechnology Information National Kidney Foundation UK Nephrology - Renal Association World Cancer Research Fund International World Health Organizations To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | May 17, 2017
Site: www.prnewswire.com

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 164-page report you will receive 84 tables and 93 figures - all unavailable elsewhere. The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. • Revenue forecasts of global erythropoietin market, segmented by product type: - Epoetin Alfa - Epoetin Beta - Darbepoetin Alfa - Biosimilars - Others This section also discusses the leading drugs as well as SWOT analysis of each submarket. • Revenue forecasts of global erythropoietin market, segmented by application: - Anemia (Cancer and HIV Treatment) - Kidney Disorders (ESRD and Dialysis) - Others Forecast for each regional market is further segmented by product type, application and country: - US - Canada - UK - Germany - France - Spain - Italy - Rest of Europe - China - Japan - India - Rest of Asia-Pacific - Brazil - Mexico - Rest of Latin America - Saudi Arabia - South Africa - Rest of Middle East and Africa • Assessment of selected leading companies that hold major market shares in the erythropoietin market: - Amgen - Johnson & Johnson - Roche - Biocon - 3SBio - Pfizer - Kyowa Hakko Kirin Co Ltd - LG Life Sciences Limited - Intas Pharmaceuticals Ltd - Novartis AG Visiongain's study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 3SBio Inc. Accord Healthcare Limited Actavis Akebia Therapeutics Amgen Astellas Pharma Inc AstraZeneca Bio Sidus SA Biocon Ltd Casa Marzam Casa Saba Chugai Pharmaceutical Claes-Göran Östenson Corvidia Therapeutics DaVita Inc Dr. Reddy's Laboratories FibroGen First Shanghai Investments Limited Fresenius Medical Care North America (FMCNA) Galenica Germans Trias i Pujol Hospital GlaxoSmithKline H. Lundbeck A/S Hoffmann-La Roche Hospira Janssen Biotech Japan Chemical Research Pharmaceuticals Co., Ltd. Johnson & Johnson Kissei pharmaceuticals Kosin University Gospel Hospital Kyowa Hakko Kirin Co Ltd LG Life Sciences Limited NADRO NovaQuest Co-Investment Fund I, L.P. Novartis Institutes for BioMedical Research (NIBR) Novartis Pharmaceuticals NOXXON Pharma AG Pfizer Proveedora de Medicamentos RPG Life Sciences Sandoz Sirton Pharma Stada Stem Cell Therapeutics Corp. Teva Pharmaceutical Industries Ltd. UBI Pharma Inc. Vifor Pharma List of Organizations Mentioned in the Report Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) Centers of Disease Control and Preventions China's Ministry of Health (MOH) Committee for Medicinal Products for Human Use (CHMP) Department of Health & Family Welfare of Karnataka Deutsches Ärzteblatt EMA European Commission (EC) FDA Indian Council of Medical Research (ICMR) International Agency for Research on Cancer (IARC) Ministry of Health, Malaysia National Cancer Institute National Center for Biotechnology Information National Kidney Foundation UK Nephrology - Renal Association World Cancer Research Fund International World Health Organizations To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


Lee D.-K.,Kosin University
Journal of the Korean Medical Association | Year: 2017

In light of global climate change, the seasonal and geographical distribution of vector species, especially mosquitoes, chigger mites, and ticks, are of great importance for human beings residing in rural and urban environments. A total of 12 species belonging to 4 genera have been identified as vector mosquitoes in the Republic of Korea. The most common of the 56 mosquito species in this country from 2013 through 2015 was found to be a malaria vector, Anopheles sinensis s.l. (species ratio [SR] 52%); followed by a potential vector of West Nile virus, Aedes vexans nipponii (SR 38%); a Japanese encephalitis vector, Culex tritaeniorhynchus (SR 6%); a West Nile virus vector, Culex pipiens (SR 3%); and a dengue and Zika virus vector, Ae. albopictus (SR 0.3%). Of the scrub typhus vectors, Leptotrombidium scutellare is the predominant chigger mite in Gyongnam province and Jeju island, whereas L. pallidum is the predominant species in other areas of Korea. Ticks were found to be prevalent in most environmental conditions, and high levels of their activity were consistently observed from May to September. Haemaphysalis species of ticks were mostly collected in grasslands, whereas Ixodes species were frequently found in coniferous forests. Haemaphysalis longicornis, known as the main vector of severe fever with thrombocytopenia syndrome, was the predominant species and was widely distributed throughout the country. © Korean Medical Association.

Loading Kosin University collaborators
Loading Kosin University collaborators